Effective influence of sacubutril/valsartan on systolic function of left ventricle in patients with heart failure and a reduced ejеction fraction

Adilova , Ikbol, Akbarova , Gulnoza, Адилова , Икбол, Акбарова , Гулноза, Адилова , Иқбол, Акбарова , Гулноза

Жамият ва инновациялар / Общество и инновации / Society and innovations · 2021-yil

Annotatsiya

Aim: We evaluated the influence of sacubitril/valsartan on the left ventricle function and clinical status of patients with heart failure and a reduced ejection fraction. Materials and methods: From 2018 to 2020, patients cured with 50-200 mg sacubitril/valsartan after coronary bypass grafting or coronary stenting for ischemic heart disease and HFrEF (aged 54-70 years) were enrolled in this prospective study. Results: There was no death case. There was a female prevalence with female to male ratio of 1,7:1. the value of ejection fraction high significantly increased (p=0,035), whereas the indices of left ventricle end-diastolic volume (p=0,015) and end-diastolic volume index (p=0,022) as well as left ventricle mass index were high significantly decreased (p=0,001) that indicate the amelioration of left ventricle systolic function. Correspondingly, the clinical status of all patients improved according to New York Heart Association Class (p=0,001). Conclusion: The post-CABG or PCI patients with HFrEF should be cured with sacubitril/valsartan basing on its implementation instruction. Nevertheless, future studies should focus on a larger cohort of post-CABG or PCI patients to compare the effectiveness and safety of sacubitril/valsartan usage raising from its adverse event in comparison to conventional therapy.

Maqola ma’lumotlari
MualliflarAdilova , Ikbol, Akbarova , Gulnoza, Адилова , Икбол, Акбарова , Гулноза, Адилова , Иқбол, Акбарова , Гулноза
JurnalЖамият ва инновациялар / Общество и инновации / Society and innovations
Nashr sanasi2021-05-20
Jild2
Son4/S
Betlar746-752
TilIngliz
DOI10.47689/2181-1415-vol2-iss4/s-pp746-752

Kalit so‘zlar

сакубутрил/валсартан, неприлизин, сниженная фракция выброса, сердечная недостаточность, левый желудочек, sacubitril/valsartan, neprilysin, reduced ejection fraction, heart failure, left ventricle, сакубутрил/валсартан, неприлизин, пасайган қискариш фракцияси, юрак етишмовчилиги, чап қоринча

Ilmiy soha

Жамият ва инновациялар / Общество и инновации / Society and innovations jurnalidan boshqa maqolalar

Жамият ва инновациялар / Общество и инновации / Society and innovations — barcha maqolalar